Organism: Homo sapiens
Gene: 38690_at
Selected probe(set): 1554149_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38690_at (1554149_at) across 6431 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-2.6688328
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.4233656
Number of Samples:3 / 6

Experimental	SDF study 4
	MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control	untreated MDA Mb231 cell sample
	Untreated MDA Mb231 cells harvested after 6h.

Relative Expression (log2-ratio):-2.3635502
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-2.1837797
Number of Samples:2 / 5

Experimental	kidney transplantation study 15 (8 week)
	CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal monocyte (CD14+) sample
	CD14+ monocyte samples derived from healthy control subjects.

Relative Expression (log2-ratio):2.1172132
Number of Samples:7 / 3

Experimental	Langerhans cell histiocytosis study 1
	Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control	normal plasmocytoid dendritic cell sample
	Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

Relative Expression (log2-ratio):2.0548353
Number of Samples:6 / 12

Experimental	IL-4; GM-CSF study 1 (early)
	Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control	untreated monocyte sample
	Freshly isolated human monocytes from healthy donors.

Relative Expression (log2-ratio):-1.9901934
Number of Samples:3 / 2

Experimental	glioma study 16 (secondary glioblastoma)
	Secondary glioma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade IV).
Control	normal brain tissue
	Normal brain tissue sample from healthy donors.

Relative Expression (log2-ratio):-1.8576555
Number of Samples:3 / 3

Experimental	CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
	CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control	CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
	Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

Relative Expression (log2-ratio):1.8574
Number of Samples:2 / 2

Experimental	LPS study 4
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):-1.8217173
Number of Samples:7 / 2

Experimental	glioma study 16 (oligodendroglioma)
	Primary oligodendroglioma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade OGII-III).
Control	normal brain tissue
	Normal brain tissue sample from healthy donors.